Sung Il Hwang1, Hak Jong Lee2, Sang Eun Lee3, Sung Kyu Hong3, Seok-Soo Byun3, Sang Chul Lee3, Gheeyoung Choe4. 1. Department of Radiology, Seoul National University Bundang Hospital, Republic of Korea. 2. Department of Radiology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Republic of Korea; Program in Nano Science and Technology, Department of Transdisciplinary Studies, Seoul National University Graduate School of Convergence Science and Technology, Republic of Korea. Electronic address: hakjlee@snu.ac.kr. 3. Department of Urology, Seoul National University Bundang Hospital, Republic of Korea. 4. Department of Pathology, Seoul National University Bundang Hospital, Republic of Korea.
Abstract
PURPOSE: We want to investigate whether MR-US fusion can improve the detection rates of clinically significant prostate cancer in patients with prior negative prostate biopsy with PSA level <10 ng/mL. METHODS: Thirty nine patients who had previous a history of negative prostate biopsy and PSA levels <10 ng/mL were included in this study. MR was performed before the biopsy and graded using PIRADS V2. We labeled patients with index lesions with PIRADS scores of 3 or above as the MR-positive group, while patients with PIRADS scores of 1 or 2 were the MR-negative group. Two cores of added biopsy (AB) were performed per each index lesion under MR-US fusion. Twelve cores randomized systematic biopsy (SB) were followed. In MR negative group, two cores of AB were obtained in transition zone, followed by SB. Overall cancer and clinically significant cancer detection rates by patients and by cores were analyzed, and compared between MR-positive and negative group. RESULTS: The overall cancer detection rates were 51.3% by patient based and 13.8% by core based. While all of AB positive cancer patients were clinically significant cancer patients, five out of seven (71.4%) AB negative cancer patients were clinically insignificant cancer patients. AB results turned another four cancer patients from insignificant to significant cancer. The cancer detection rates between MR-positive and negative group were statistically significant. CONCLUSIONS: Additional biopsy using MR-US fusion showed improved detection of clinically significant prostate cancer.
PURPOSE: We want to investigate whether MR-US fusion can improve the detection rates of clinically significant prostate cancer in patients with prior negative prostate biopsy with PSA level <10 ng/mL. METHODS: Thirty nine patients who had previous a history of negative prostate biopsy and PSA levels <10 ng/mL were included in this study. MR was performed before the biopsy and graded using PIRADS V2. We labeled patients with index lesions with PIRADS scores of 3 or above as the MR-positive group, while patients with PIRADS scores of 1 or 2 were the MR-negative group. Two cores of added biopsy (AB) were performed per each index lesion under MR-US fusion. Twelve cores randomized systematic biopsy (SB) were followed. In MR negative group, two cores of AB were obtained in transition zone, followed by SB. Overall cancer and clinically significant cancer detection rates by patients and by cores were analyzed, and compared between MR-positive and negative group. RESULTS: The overall cancer detection rates were 51.3% by patient based and 13.8% by core based. While all of AB positive cancerpatients were clinically significant cancerpatients, five out of seven (71.4%) AB negative cancerpatients were clinically insignificant cancerpatients. AB results turned another four cancerpatients from insignificant to significant cancer. The cancer detection rates between MR-positive and negative group were statistically significant. CONCLUSIONS: Additional biopsy using MR-US fusion showed improved detection of clinically significant prostate cancer.
Authors: E J Bass; A Pantovic; M J Connor; S Loeb; A R Rastinehad; M Winkler; Rhian Gabe; H U Ahmed Journal: Prostate Cancer Prostatic Dis Date: 2021-09-21 Impact factor: 5.455